Bazedoxifene acetate is a non-steroidal, indole-based compound, acts as anti-osteoporotic agent.
It is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture and for the reduction in the incidence of vertebral fractures.
It is formulated as film coated tablets or tablets for the oral route of administration.
Mechanism of action:
Bazedoxifene acetate acts as both an estrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone remodeling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures.